A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 3, 2011, Pages 592-599

  Golabi, Nahid ^a   Brahimi, Fouad ^a   Huang, Ying ^a   Rachid, Zakaria ^a   Qiu, Qiyu ^a   Larroque Lombard, Anne Laure ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Combi molecule; DNA damage; EGFR; In vitro; In vivo

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; UNCLASSIFIED DRUG; ZR 2003;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT; VULVA CARCINOMA;

ANIMALS; ANTINEMATODAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DNA DAMAGE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; OVARIAN NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIAZENES; VULVAR NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79961128455     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.06.013     Document Type: Article

References (20)

1. Brahimi F., Matheson S.L., Dudouit F., McNamee J.P., Tari A.M., Jean-Claude B.J. Inhibition of epidermal growth factor receptor-mediated signaling by "combi-triazene" BJ2000, a new probe for combi-targeting postulates. J. Pharmacol. Exp. Ther. 2002, 303:238-246.
2. Qiu Q., Domarkas J., Banerjee R., Merayo N., Brahimi F., McNamee J.P., Gibbs B.F., Jean-Claude B.J. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin. Cancer Res. 2007, 13:331-340.
3. Banerjee R., Huang Y., McNamee J.P., Todorova M., Jean-Claude B.J. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. J. Pharmacol. Exp. Ther. 2010, 334:9-20.
4. Banerjee R., Rachid Z., McNamee J., Jean-Claude B.J. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J. Med. Chem. 2003, 46:5546-5551.
5. Qiu Q., Domarkas J., Banerjee R., Katsoulas A., McNamee J.P., Jean-Claude B.J. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anticancer Drugs 2007, 18:171-177.
6. Rachid Z., Brahimi F., Domarkas J., Jean-Claude B.J. Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status. Bioorg. Med. Chem. Lett. 2005, 15:1135-1138.
7. Brahimi F., Rachid Z., Qiu Q., McNamee J.P., Li Y.-J., Tari A.M., Jean-Claude B.J. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int. J. Cancer 2004, 112:484-491.
8. Moss N.M., Barbolina M.V., Liu Y., Sun L., Munshi H.G., Stack M.S. Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in i.p. metastatic dissemination. Cancer Res. 2009, 69:7121-7129.
9. Grun B., Benjamin E., Sinclair J., Timms J.F., Jacobs I.J., Gayther S.A., Dafou D. Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif. 2009, 42:219-228.
10. Lawrenson K., Benjamin E., Turmaine M., Jacobs I., Gayther S., Dafou D. In vitro three-dimensional modelling of human ovarian surface epithelial cells. Cell Prolif. 2009, 42:385-393.
11. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82:1107-1112.
12. Nociari M.M., Shalev A., Benias P., Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J. Immunol. Methods 1998, 213:157-167.
13. Todorova M.I, Larroque A.L., Dauphin-Pierre S., Fang Y.Q., Jean-Claude B.J. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol. Cancer Ther. 2010, 9:869-882.
14. Diaz R., Nguewa P.A., Parrondo R., Perez-Stable C., Saenz de Tejada I., Redrado M., Catena R., Collantes M., Penuelas I., Diaz-Gonzalez J.A., Calvo A. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 2010, 10:188-197.
15. Jones J., Takeda A., Picot J., von Keyserlingk C., Clegg A. Lapatinib for the treatment of HER2-overexpressing breast cancer. Health Technol. Assess. 2009, 13(Suppl. 3):1-6.
16. Pytel D., Sliwinski T., Poplawski T., Ferriola D., Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med. Chem. 2009, 9:66-76.
17. Steeghs N., Nortier J.W., Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 2007, 14:942-953.
18. Arora A., Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005, 315:971-979.
19. Kaufman H., Wadler S., Antman K. Molecular Targeting in Oncology 2008, Humana Press.
20. Watt H.L., Rachid Z., Jean-Claude B.J. Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting. J. Neurooncol. 2010, 100:345-361.